C. Gersch

发表

Predictors of recovery of ovarian function during aromatase inhibitor therapy.

M. Banerjee, D. Hayes, D. McConnell, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms.

A. Chinnaiyan, Dafydd G. Thomas, S. Tomlins, 2018, Cancer research.

Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms

J. Douglas, D. Hayes, T. Skaar, 2022, Supportive Care in Cancer.

Metabolites of n-Butylparaben and iso-Butylparaben Exhibit Estrogenic Properties in MCF-7 and T47D Human Breast Cancer Cell Lines

H. Koch, Michael D. Johnson, J. Rae, 2018, Toxicological sciences : an official journal of the Society of Toxicology.

PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer

Dafydd G. Thomas, D. Hayes, J. Rae, 2021, PloS one.

Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms

J. Douglas, D. Hayes, T. Skaar, 2022, Supportive Care in Cancer.

Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma

B. Redman, A. Alva, J. Rae, 2018, Investigational New Drugs.

Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients

D. Hayes, T. Skaar, V. Stearns, 2017, Breast Cancer Research and Treatment.

Impact of pharmacogenetics on intravenous tacrolimus exposure and conversions to oral therapy.

J. Rae, K. Kidwell, Gianni B. Scappaticci, 2021, Transplantation and cellular therapy.

Genetic variation in EPHA contributes to sensitivity to paclitaxel‐induced peripheral neuropathy

J. Griggs, D. Hayes, J. Rae, 2019, British journal of clinical pharmacology.

Impact of CYP3A5 phenotype on tacrolimus concentrations after sublingual and oral administration in lung transplant.

J. Rae, J. Dempsey, K. Kidwell, 2019, Pharmacogenomics.

Genotyping concordance in DNA extracted from formalin‐fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses

M. Regan, J. Rae, C. V. Van Poznak, 2015, Molecular oncology.

Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer

Shaomeng Wang, D. Hayes, Jiantao Hu, 2020, Breast Cancer Research and Treatment.

Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity

J. Douglas, D. Hayes, T. Skaar, 2021, Pharmacogenetics and genomics.

Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

L. Pusztai, Dafydd G. Thomas, B. Leyland-Jones, 2013, Journal of the National Cancer Institute.

Evaluating the Impact of CYP3A5 Genotype on Post-Transplant Healthcare Resource Utilization in Pediatric Renal and Heart Transplant Recipients Receiving Tacrolimus

M. Englesbe, J. Rae, Amy L. Pasternak, 2021, Pharmacogenomics and personalized medicine.

PGPM_A_285444 319..326

M. Englesbe, J. Rae, Amy L. Pasternak, 2021 .

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

Daniel F. Hayes, Arul M. Chinnaiyan, Heather A. Parsons, 2015, Clinical Cancer Research.

Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor–Positive Breast Cancers

L. Pierce, Meilan Liu, C. Speers, 2020, Clinical Cancer Research.

Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer

A. Blackford, V. Stearns, J. Rae, 2021, Frontiers in Genetics.

Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy.

D. Hayes, J. Rae, E. Smith, 2020, Pharmacogenomics.

Osteonecrosis of the Jaw Risk Factors in Bisphosphonate Treated Patients with Metastatic Cancer.

M. Banerjee, Dafydd G. Thomas, D. Hayes, 2020, Oral diseases.

Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole.

D. Hayes, T. Skaar, V. Stearns, 2019, Pharmacogenomics.

Is incomplete estradiol suppression during aromatase inhibitor treatment in post-menopausal patients with breast cancer due to insufficient systemic drug concentrations?

D. Hayes, T. Skaar, V. Stearns, 2017 .

Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines.

Nicholas J. Seewald, J. Griggs, M. Rubenfire, 2016, Pharmacogenomics.

EPHA genetics for prediction of paclitaxel-induced peripheral neuropathy sensitivity.

J. Griggs, D. Hayes, E. Smith, 2019, Journal of Clinical Oncology.

Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer

Steffi Oesterreich, Todd C. Skaar, David A. Flockhart, 2013, Breast Cancer Research and Treatment.

Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion

D. Hayes, V. Stearns, J. Rae, 2019, Breast Cancer Research and Treatment.

Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in post-menopausal patients with breast cancer

Nicholas J. Seewald, D. Hayes, T. Skaar, 2016, The Pharmacogenomics Journal.

ESR 1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

Daniel F. Hayes, Arul M. Chinnaiyan, Heather Parsons, 2015 .

Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms

J. Lehman, D. Hertz, C. Gersch, 2024, Pharmacogenetics and genomics.

Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer.

D. McEachern, Biao Hu, Shaomeng Wang, 2024, Journal of medicinal chemistry.